A Rare Opportunity? NIH Program For Rare Diseases May Have Big Payoff For Drug Development
This article was originally published in RPM Report
Executive Summary
NIH Director Francis Collins is very excited about a $24 million program to de-risk small molecule treatments for rare disorders. You should be too.
You may also be interested in...
Sustainable Funding for Regulatory Science: FDA, Industry Hope Fourth Time is the Charm
FDA is trying one more time to secure significant resources to fund regulatory science. FDA's leadership is making good progress with key figures in the Administration and on the Hill-but the money still isn't there.
Sustainable Funding for Regulatory Science: FDA, Industry Hope Fourth Time is the Charm
FDA is trying one more time to secure significant resources to fund regulatory science. FDA's leadership is making good progress with key figures in the Administration and on the Hill-but the money still isn't there.
Doing Well By Doing Good: FDA's Orphan Product Head Makes His Case to Pharma
Tim Coté has been a tireless advocate for greater involvement by Big Pharma in orphan drug research since taking over as head of FDA's Orphan Products Office two years ago. We talked to him about the response he's heard so far.